direct acting antiviral drugs
<p>Direct-Acting Antiviral Drugs and Occurrence of Hepatocellular Carcinoma: Unjust or Oppressed</p>
... therapies. Direct-acting antiviral agents (DAAs) have achieved high eradication rates with an excellent safety pro- fi le since revolutionized the management of HCV ...
8
EVALUATION OF THE EFFICACY AND SAFETY OF COMPLEX THERAPY OF ACUTE RESPIRATORY DISEASES OF ADENOVIRAL ETIOLOGY IN YOUNG PEOPLE
... indirect-acting antiviral agents are currently used to treat acute respiratory diseases, including adenoviral ...that direct-acting antiviral drugs (ribavirin and umifenovir) ...
10
Direct acting antiviral agents in the therapy of hepatitis C virus related mixed cryoglobulinaemia: a single centre experience
... the antiviral combination of pegylated interferon-α plus ribavirin (pIFN-α + RBV) was employed to obtain a sustained virological response (SVR), and for many years, this combination has been considered the ...
10
Adoption of direct acting antiviral medications for hepatitis C: a retrospective observational study
... These data suggest that an initial surge of early adopters prescribed the new medications and use dwindled over time as the initial HCV cohort was cured, including many patients who had been delaying therapy in antici- ...
7
Hepatitis C in healthcare personnel: secondary data analysis of therapies with direct-acting antiviral agents
... Healthcare personnel (HP) have contact with infected patients as part of their work. Injuries caused by sharp or pointed objects are some of the most commonly re- ported workplace accidents [10]. In Germany, reports ...
8
Price and affordability of direct-acting antiviral regimens for hepatitis C virus in the United States
... Medicare is a federally subsidized insurance available to Americans aged 65 or older and younger people with disabilities. Medicare Part D is the prescription drug benefit for Medicare beneficiaries, established in 2003 ...
8
Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents
... To date, a limited number of drugs are approved for the treatment of chronic HCV infection. Thus, patients with gene variations associated with inadequate response may have no alternatives for treatment, leading ...
17
The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon based treatment with first generation protease inhibitors a multicenter cohort study
... Progress achieved in recent years in the treatment of pa- tients with viral hepatitis C has enabled elimination of hepatitis C virus (HCV) infection in most patients. This progress has been achieved through the use of ...
9
A systematic review and meta analysis of community and primary care based hepatitis C testing and treatment services that employ direct acting antiviral drug treatments
... studies originated from United States of America (8); Australia (5); United Kingdom (2); and Canada (2). The number of identified studies published as conference ab- stracts reflected the length of time that DAAs have ...
13
Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017
... However, this study has several limitations. As the pa- tients were included each calendar year with a dosage criteria, a patient who commenced treatment late or quit early during the year may not obtain sufficient ...
10
Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era
... antiretroviral drugs, but not HBV, may further drive hepatic ...to direct-acting antivirals appear not to be ...of direct-acting ...
7
Safety and efficacy of elbasvir/grazoprevir for the treatment of chronic hepatitis C: current evidence
... ment for HCV infection has significantly improved since the advent of direct-acting antiviral (DAA) agents, such as boceprevir and telaprevir. First-generation DAAs with concomitant use of Pegylated ...
8
A study of the circulating fibroblast growth factor 21 as a novel noninvasive biomarker of hepatic injury in genotype-4 chronic hepatitis C: Egyptian patients and their response to direct-acting antiviral agents
... tions of systemic FGF21 with HOMA-IR in HCV-infected patients. The discrepancy between the different studies may be explained by the direct involvement of the HCV with IR and the non-excluded interference between ...
8
Prevalence of hepatitis C virus-resistant association substitutions to direct-acting antiviral agents in treatment-naïve hepatitis C genotype 1b-infected patients in western China
... To our knowledge, this study is the first to report the prevalence of RASs in western Chinese chronic HCV 1b patients. Moreover, the latest and most comprehensive panel of clinically relevant RASs was included to analyze ...
16
Severe Guillain Barré syndrome associated with chronic active hepatitis C and mixed cryoglobulinemia: a case report
... by antiviral therapy by direct-acting antiviral agent, patient showed progressive recovery and was transferred 3 months after his first admission to a rehabilitation ...
5
Vol 32, No 3 (2019)
... limit. Direct-acting antivirals regimens resulted in remarkably high SVR rates compared to interferon-based regimens, which were consistent with clinical trials ...
6
<p>Hepatitis C Antiviral Therapy In Patients With Successfully Treated Hepatocellular Carcinoma: Dancing With Wolves</p>
... with direct-acting antivirals (DAAs) as a new method for HCV treatment and cure in 2014, with higher safety and ef fi cacy, were considered as an important step in the treatment of patients with history of ...
9
<p>Prevalence and predictors of occult hepatitis C virus infection among Egyptian patients who achieved sustained virologic response to sofosbuvir/daclatasvir therapy: a multi-center study</p>
... Results: HCV-RNA was detected in PBMCs of 50 (3.9%) of them. All OCI cases exhibited significant fibrosis score and raised pre-treatment alanine aminotransferase (ALT) levels. Logistic regression analysis comparing OCI ...
7
The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments
... In each scenario, a deterministic model of HCV transmission among PWID was used to predict 1 the additional prevalence reduction that could be achieved by vaccinating after treatment and[r] ...
12
Rapid Development of Hepatocellular Carcinoma after Eradication of Hepatitis C Virus with Directly Acting Antiviral Treatment
... [1]. Antiviral therapy has been available since the early ...of direct-acting antivirals (DAAs) in the armamentarium has in- creased the HCV cure rates well above 90% even in patients with bridging ...
11